NCT02006108View on ClinicalTrials.gov

Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 27, 2012

Primary Completion Date

April 11, 2017

Study Completion Date

April 11, 2017

Conditions
Renal Transplant Rejection
Interventions
DRUG

Feraheme

Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging

OTHER

MRI-GE Healthcare 3 Tesla magnet

All patients will undergo

Trial Locations (1)

94305

Lucile Packard Children's Hospital, Stanford

All Listed Sponsors
collaborator

Lucile Packard Children's Hospital

OTHER

lead

Stanford University

OTHER

NCT02006108 - Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance | Biotech Hunter | Biotech Hunter